Covid: AstraZeneca ‘imminently’ scaling up to 2 million vaccine doses per week

Company president says 1.1 million doses have been released to UK so far

Samuel Osborne
Wednesday 13 January 2021 15:10
Comments
Tom Keith-Roach says company may be able to go above two million doses from April
Tom Keith-Roach says company may be able to go above two million doses from April

AstraZeneca will “imminently” scale up production to release 2 million doses of its vaccine each week in the UK, the firm’s chief executive has said.

Tom Keith-Roach, the president of AstraZeneca UK, said the company may be able to go above that figure from April onwards.

He said 1.1 million doses of the company’s Covid-19 jab, which was developed with Oxford University, have been released to the UK so far, but the aim was to reach 2 million doses per week on or before the middle of February.

He told the Commons Science and Technology Committee: "We are scaling up very rapidly – and this will happen imminently – to releasing 2 million doses a week.

"We're absolutely on track to do that and therefore deliver tens of millions of doses in the first quarter of the year.

"If we average 2 million a week through the course of the year, that gets us to the 100 million doses that we're committed to the UK through the course of 2021."

Later, he added: "We are scaling up to 2 million doses a week imminently and we'd certainly hope to be there on or before the middle of February."

He said the middle of February was a "conservative position" and said the firm had been asked by the UK Vaccines Taskforce not to share in public details of daily delivery schedules and locations for security reasons.

"As you can imagine it's very sensitive, but I can reassure you that we will scale to 2 million doses per week very quickly."

Later, he said the firm could not commit to doses above 2 million per week but might be able to "increase that somewhat as we move into quarter two".

Mr Keith-Roach also told MPs the manufacture of the vaccine depends on a complex biological process which cannot be carried out more quickly.

"Drug substance manufacture is a 58- to 60-day process that you cannot speed up – that is a complex biological process of actually growing the adenovirus vector," he said.

Mene Pangalos, executive vice president of biopharmaceuticals research and development at AstraZeneca, added: "You have to grow cells and cells divide at a certain speed, and you can't do any faster than the speed at which the cells divide."

Mr Keith-Roach added: "From drug substance, you have to actually manufacture the drug product.

"That includes filling and finishing, packaging, batch release – that takes a further 28 days.

"If you look in total, you're talking about a three- to four-month process.

"Within that you have, as you'd imagine, extensive quality testing on every batch. Actually there's more than 60 quality tests that are performed."

Additional reporting by Press Association

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in